Trials / Recruiting
RecruitingNCT06807502
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 93 (estimated)
- Sponsor
- ScreenCell · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | The DM/DIV ScreenCell is the experimental product studied during this research | The product is not used directly on the subject, but on a blood sample taken from the participant. |
Timeline
- Start date
- 2025-02-24
- Primary completion
- 2026-09-30
- Completion
- 2026-11-30
- First posted
- 2025-02-04
- Last updated
- 2025-03-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06807502. Inclusion in this directory is not an endorsement.